Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
AssigneeNovartis AG
InventorsMirek DOSTALEK, Claire FABRE, Fariba KHANSHAN
Life of this patent
Estimating the term…
Abstract
Therapies using TGF-β inhibitors and/or PD-1 inhibitors are disclosed. These drugs at certain doses (including flat dosing) and regimens can be used to treat or prevent proliferative diseases such as solid tumors, including pancreatic cancers. Further combination and uses thereof are also disclosed.
Claims55
A method of treating a proliferative disease in a subject in need thereof comprising administering to the subject a TGF-β antibody at a dose of about 16 mg/kg to about 50 mg/kg, once every two or three weeks, wherein the TGF-β antibody comprises a heavy chain CDR1, CDR2, and CDR3, of SEQ ID NOs:
- 1, 2, and 3, respectfully, and a light chain CDR1, CDR2, and CDR3, of SEQ ID NOs:
- 4, 5, and 6, respectfully.
A method of treating a proliferative disease in a subject in need thereof comprising administering to the subject a TGF-β antibody at a dose of about 1200 mg to about 1600 mg, once every two or three weeks, wherein the TGF-β antibody comprises a heavy chain CDR1, CDR2, and CDR3, of SEQ ID NOs:
- 1, 2, and 3, respectfully, and a light chain CDR1, CDR2, and CDR3, of SEQ ID NOs:
- 4, 5, and 6, respectfully.
A method of treating a proliferative disease comprising administering to a subject in need thereof a TGF-β antibody at a dose of about 1900 mg to about 2300 mg, once every two or three weeks, wherein the TGF-β antibody comprises a heavy chain CDR1, CDR2, and CDR3, of SEQ ID NOs:
- 1, 2, and 3, respectfully, and a light chain CDR1, CDR2, and CDR3, of SEQ ID NOs:
- 4, 5, and 6, respectfully.
A method of treating pancreatic ductal adenocarcinoma comprising administering to a subject in need thereof a TGF-β antibody at a dose of 2100 mg, once every two or three weeks, wherein the TGF-β antibody comprises the heavy chain and light chain set out in amino acid sequence of SEQ ID NOs:
- 9 and 10, respectively.
A method of treating colorectal cancer comprising administering to a subject in need thereof a TGF-β antibody at a dose of 2100 mg, once every two or three weeks, wherein the TGF-β antibody comprises the heavy chain and light chain set out in amino acid sequence of SEQ ID NOs:
- 9 and 10, respectively.
A method of treating pancreatic ductal adenocarcinoma comprising administering to a subject in need thereof a TGF-β antibody at a dose of 1400 mg, once every two weeks, wherein the TGF-β antibody comprises the heavy chain and light chain set out in amino acid sequence of SEQ ID NOs:
- 9 and 10, respectively.
A method of treating colorectal cancer comprising administering to a subject in need thereof a TGF-β antibody at a dose of 1400 mg, once every three weeks, wherein the TGF-β antibody comprises the heavy chain and light chain set out in amino acid sequence of SEQ ID NOs:
- 9 and 10, respectively.
A pharmaceutical composition comprising a TGF-β antibody and a pharmaceutically acceptable excipient, wherein the TGF-β antibody comprises the heavy chain and light chain set out in amino acid sequence of SEQ ID NOs:
- 9 and 10, respectively.
Dependencies are inferred from the claim text.